Woodline Partners’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $17.7M | Buy |
1,892,751
+948
| +0.1% | +$8.88K | 0.09% | 313 |
|
|
2025
Q1 | $23.2M | Hold |
1,891,803
| – | – | 0.15% | 199 |
|
|
2024
Q4 | $25M | Sell |
1,891,803
-4,229
| -0.2% | -$55.9K | 0.17% | 175 |
|
|
2024
Q3 | $36.5M | Buy |
1,896,032
+350,504
| +23% | +$6.75M | 0.31% | 101 |
|
|
2024
Q2 | $31.7M | Buy |
1,545,528
+1,241
| +0.1% | +$25.5K | 0.3% | 100 |
|
|
2024
Q1 | $36.8M | Buy |
1,544,287
+71
| +0% | +$1.69K | 0.34% | 88 |
|
|
2023
Q4 | $33.4M | Buy |
1,544,216
+1,510,149
| +4,433% | +$32.6M | 0.36% | 79 |
|
|
2023
Q3 | $495K | Sell |
34,067
-578,249
| -94% | -$8.4M | 0.01% | 495 |
|
|
2023
Q2 | $12.8M | Buy |
+612,316
| New | +$12.8M | 0.15% | 175 |
|
|
2022
Q4 | – | Sell |
-789,273
| Closed | -$19M | – | 835 |
|
|
2022
Q3 | $19M | Buy |
+789,273
| New | +$19M | 0.27% | 109 |
|
|
2022
Q1 | – | Sell |
-310,377
| Closed | -$6.79M | – | 812 |
|
|
2021
Q4 | $6.79M | Sell |
310,377
-270,931
| -47% | -$5.93M | 0.1% | 247 |
|
|
2021
Q3 | $11.1M | Buy |
581,308
+373,496
| +180% | +$7.14M | 0.18% | 146 |
|
|
2021
Q2 | $3.57M | Buy |
+207,812
| New | +$3.57M | 0.07% | 268 |
|
|
2021
Q1 | – | Sell |
-77,699
| Closed | -$1.73M | – | 471 |
|
|
2020
Q4 | $1.73M | Buy |
+77,699
| New | +$1.73M | 0.05% | 200 |
|